Modelling the value of innovative treatments for Alzheimer's disease in the United States
| Autor: | Peter J. Neumann, Sue Peschin, Dana P. Goldman, Charles Makin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Value (ethics)
medicine.medical_specialty Disease Clinical manifestation 03 medical and health sciences 0302 clinical medicine Cost of Illness Alzheimer Disease Health care medicine Dementia Humans Intensive care medicine Cause of death business.industry 030503 health policy & services Health Policy Cost-effectiveness analysis Health Care Costs medicine.disease United States Quality-adjusted life year Caregivers 030220 oncology & carcinogenesis 0305 other medical science business |
| Zdroj: | Journal of medical economics. 24(1) |
| ISSN: | 1941-837X |
| Popis: | Alzheimer's disease (AD) is the predominant cause of dementia and a leading cause of death globally. With no cure or treatment to slow disease progression, AD-related healthcare costs are substantial and increase as the severity of the disease progresses. Given the complexity of this disease, including initial pathophysiological damage occurring decades before clinical manifestation, finding new impactful treatments for AD relies on highly innovative research and development. However, such sizable and sustained investments bring into question whether conventional value assessment models are fit for this purpose. In this article, we examine the importance and challenges of assimilating the perspectives of varied stakeholders, including patients, caregivers, health systems, payers, and society at large, into a comprehensive value assessment model that may be well suited for a breakthrough treatment for AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|